Bortezomib (PS-341)

Catalog No.S1013 Synonyms: LDP-341, MLM341

Bortezomib (PS-341) Chemical Structure

Molecular Weight(MW): 384.24

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.

Size Price Stock Quantity  
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 149 Publications

25 Customer Reviews

  • Immunoblot analysis of cell lysates from the indicated cell lines treated with GNE-6776 (2 μ M for 18 h), either alone or in combination with a UAE1 inhibitor MLN-7243 (5 μ M for 45 min) or the proteasome inhibitor bortezomib (5 μ M for 45 min) as indicated.

    Nature, 2017, 550(7677):534-538. Bortezomib (PS-341) purchased from Selleck.

    Indisulam dependent degradation of RBM39 can be blocked by bortezomib, a proteasome inhibitor. Cells were pretreated with indicated concentrations of bortezomib for 2 hours, followed by 6 hours of treatment with 2 μM indisulam. The effect of bortezomib is attenuated in a bortezomib resistant cell line.

    Science, 2017, eaal3755. Bortezomib (PS-341) purchased from Selleck.

  • Wild-type mice fed as indicated were injected with vehicle (10% DMSO, pH 7.4 PBS) or bortezomib (5 mg/kg bodyweight). Livers were collected 16 hr later for quantitative PCR analysis of indicated genes (n = 4–5). *p < 0.05 bortezomib effect and #p < 0.05 Chol-Diet effect by two-way ANOVA.

    Cell, 2017, 171(5):1094-1109. Bortezomib (PS-341) purchased from Selleck.

    Effect of different proteasome inhibitors on dysferlin expression and on membrane resealing in cultured primary myoblasts. Primary myoblasts from patient 2 harboring a homozygous Arg555Trp DYSF mutation that were treated with the indicated amounts of bortezomib for 24 hours. Western blots of protein extracts were stained with anti-dysferlin antibodies and with anti–a-tubulin antibody as loading control.

    Sci Transl Med 2015 6(250), 250ra112. Bortezomib (PS-341) purchased from Selleck.

  • Pharmacologic inhibition of the proteasome blocks proplatelet formation in murine and human megakaryocytes. Human megakaryocytes were pretreated with vehicle or bortezomib, and megakaryocytes producing proplatelets (PP) were examined. Shown are representative transmission images and representative confocal images with wheat germ agglutinin (WGA; red) and phalloidin (green) staining. Scale bars: 50 um.

    J Clin Invest 2014 124(9), 3757-66. Bortezomib (PS-341) purchased from Selleck.

    Effects of NF-kB inhibition on cell proliferation and apoptosis in Foxp3cKO prostate. A. Top left panels: Representative H&E staining of PIN lesions in ventral prostates of 60-week-old PBS- or bortezomib-treated Foxp3cKO littermates. Scale bar, 50 祄. Right graph: Quantification of Ki67-positive cells identified by IHC analysis (bottom left panels) as a measure of cell proliferation, performed with Scion Image software. Horizontal lines represent the average values. The p value was determined by two-tailed t test. B. Representative western blots showing p65 and nuclear p65 (N-p65) expression in prostates at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. C. Quantification of Bcl2l1 and Traf1/2 mRNA expression as a percentage of Hprt expression measured in microdissected mouse prostate epithelial cells by qPCR at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. Horizontal lines represent the average values. The p values were determined by two-tailed t test. D. Left panels: Representative images of TUNEL assays performed on prostates from PBS- or bortezomib-treated mice at 60 weeks of age. Insets show the apoptotic cells (green) in prostate glands. Scale bar, 100 祄. Right graph: Quantification of apoptotic cells in the ventral and dorsolateral prostates of PBS- or bortezomib-treated mice at 45 and 60 weeks of age. Horizontal lines represent the average values. The p value was determined by two-tailed t test. cKO, PB4-Cre4+Foxp3flox/y; wks, weeks; B/P, ratio of the mean value from bortezomib-treated mice to the mean value in PBS-treated mice. All experiments were repeated two times. Wks, weeks.

    Cancer Res 2015 75(8), 1714-24. Bortezomib (PS-341) purchased from Selleck.

  • Immunofluorescence showing HDAC4 localization in mouse primary osteoblasts treated with vehicle or PTH alone or in the presence of bortezomib. Primary osteoblasts treated with vehicle, PTH, or PTH plus bortezomib for 2 h using anti-HDAC4 and anti-b-actin antibodies.

    J Cell Biol 2014 205(6), 771-80. Bortezomib (PS-341) purchased from Selleck.

    Inhibition of proteasome and lysosome or silencing of VCP and co-factors lead to the accumulation of OP-puro-labeled DRIPs adjacent to or within SGs. HeLa cells were co-treated for 45 min with OP-puro and arsenite (Ars.); where indicated, cells were pretreated with bortezomib (Bort.) overnight and/or ammonium chloride (NH4Cl) for 2 h 15 min. Cells were fixed and labeled with Alexa594-Azide and anti-TIA-1.

    Cell Death Differ 2014 21(12), 1838-51. Bortezomib (PS-341) purchased from Selleck.

  • Immunofluorescence analysis for Ser536 p-NF-κB cellular localization of RS4;11cells treated with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. Cells were treated, collected at 22 h and reacted with an antibody to Ser536 p-NF-κB which was revealed by a Cy3-conjugated secondary antibody. DAPI was used to label nuclei.

    Oncotarget, 2015, 51: S659-S660. Bortezomib (PS-341) purchased from Selleck.

    Control wild-type and Fmn2–/–oocytes observed at different stages of meiotic maturation [prophase I (Pro I), NEBD, 3 hours and 8 hours after NEBD] using anti-Fmn2. wt + Bortezo, wild-type oocytes treated with 0.1μM Bortezomib for 90 minutes before fixation. All oocytes were observed using the same settings and the images treated the same way (three independent experiments). Red arrows indicate cortical labeling. Scale bar: 10μm.

    Development 2011 138, 2903-2908. Bortezomib (PS-341) purchased from Selleck.

  • Cell viability of HCT116 cells treated with a single drug or with the addition of leucovorin.

    Sci Rep, 2017, 7(1):682. Bortezomib (PS-341) purchased from Selleck.

    (B–C) LNCaP (B) and LNCaP-AI (C) cells were transiently transfected with sPLA2-IIa(-800)-Luc (0.5 μg). The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) without or with EGF (100 ng/ml) for 24 h. Luciferase assay was performed according to a standard protocol with Renilla luciferase as an internal control. Data are presented as the mean (±SD) of duplicate values of a representative experiment that was independently repeated for five times.

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

  • LNCaP-AI cells were starved in 1% stripped medium for 24 h. The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) for 24 h. Cell culture medium was collected from each sample and subjected to ELISA for sPLA2-IIa. The condition medium samples were diluted 10 times for ELISA. Average of duplicate samples was converted to nanogram per milliliter against standard curve. The data represent one of five repeated experiments.

     

     

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

    Western blot of extracts of infected cells treated with different proteasome inhibitors at different concentrations, reacted with the indicated antibodies. p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Time window treatment with proteasome inhibitors. (A) Scheme of the experiment performed with MA104 cells exposed to virus (OSU; MOI, 3) for 1 h and analyzed at the starting point and endpoint of the indicated time window treatments with DMSO, MG132, or bortezomib. (B) Western blot of cellular lysates derived from cells infected for the indicated time periods and treated with the proteasome inhibitors or DMSO. NI, noninfected cells. Blots were reacted with the indicated antibodies; p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Fluorescence analysis of viroplasm formation on NSP5-EGFP cells infected with rotavirus (OSU; MOI, 3) and treated or not treated with MG132 (10 M) or bortezomib (10 M) at different times p.i., as indicated. Cells were analyzed at the starting points (1 h, 3 h, 5 h, 7 h) and endpoints (9 h) of the inhibitor’s window treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Quantification of the accumulation of viroplasms in infected NSP5 -EGFP/MA104 cells. At different times p.i., cells were treated for 4 h with DMSO or the indicated proteasome inhibitor and the number of viroplasms/cell was quantified at the starting (1 h, 3 h, 5 h; white bars) and endpoints (5 h, 7 h, 9 h) of treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    PS-341 impairs FPV replication in A549 cells. (A and B)A549 cells were either pretreated for 1 h with different concentrations of PS-341 or with solvent only or were left untreated. Then, cells were infected with FPV at an MOI of 0.001 (A) or 0.05 (B). After virus inoculation cells were posttreated with different concentrations of PS-341. (A) At 24 h p.i. supernatants were obtained and progeny virus titers were measured by standard plaque assay. (B)Proteasome activity and the ability of PS-341 to inhibit the proteasome was determined 24 h p.i. (C) A549 cells were pretreated with 50 nM PS-341 or solvent or left untreated for 1 h. Afterwards cells were infected with FPV at an MOI of 0.0005. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or solvent or left untreated. After the indicated times p.i.supernatants were obtained and progeny virus titers were determined by standard plaque assay. Arrow bars in all experiments represent standard deviations of three independent experiments.

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • Early steps of viral replication within the first replication cycle are affected. (A) For time-of-addition kinetics analysis, A549 cells were either left untreated or were pretreated for 10 h or 1 h with 50 nM PS-341 before infection and additionally posttreated after infection. Cells were infected with FPV at an MOI of 0.005. After virus inoculation cells were posttreated with 50 nM PS-341. Then the proteasome inhibitor was added after virus inoculation (10 h, 1 h, and 30 min) or it was added at the different times p.i. as indicated (1 h, 2 h, 4 h, 6 h, and 8 h; cells were not pretreated before infection). At 9 h p.i. supernatants were obtained and progeny virus titers were determined by standard plaque assay. Shown is one representative experiment out of three independent experiments. (B) A549 cells were pretreated with 50 nM PS-341 or left untreated for 1 h. Afterwards cells were infected with avian FPV or human PR8 at an MOI of 1. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or left untreated. After the indicated times p.i. cells were lysed and analyzed by Western blotting for accumulation of viral proteins polymerase PB1 and matrix protein M1. Cellular protein ERK2 served as a control to demonstrate equal amounts of protein loading. Shown is one representative blot out of three independent experiments.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    A549 cells were treated with PS-341 at 50 nM for the indicated times or left untreated. Western blotting was performed with total cell lysates, using phospho-specific antibodies against JNK and the transcription factors c-Jun and ATF-2 or loading controls, respectively.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • The stable cell line HepAD38 was incubated for 18 h in the presence of the indicated amount of Bortezomib. The medium was removed and replaced by medium containing Bortezomib dissolved in PBS. In case of the control cells the same amount of PBS was added to the medium. 4 h later this procedure was repeated and again 14 h later the supernatant was collected. The amount of viral particles was quantified by real time PCR. HBV-genome quantification was done using COBAS® AmpliPrep/COBAS® TaqMan® HBV test (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s instructions. The assay shows relative values (the value for untreated control cells was arbitrarily set as 1) that are based on three independent experiments. The cell viability was analyzed by MTT assays. For does up to 50 nM no significant effect on cell viability was observed within 18h, for 100 nM the proportion of metabolically active cells was reduced to 83%.

    J Biol Chem 2010 285, 41074-41086. Bortezomib (PS-341) purchased from Selleck.

    HLC-1 cells were treated with IFN-gamma (30 ng/ml) and Bortezomib (0-10 nM) for 3 h. After washing with PBS, the cells were cultured for another 45 h in the fresh medium. After 48 h incubation, PD-L1 expression was analysed by flow cytometry (n =3).

    Int Immunopharmacol, 2018, 54:39-45. Bortezomib (PS-341) purchased from Selleck.

  • Proteasome inhibition effect on biotinylation of MHC-Iα. (a) WB-ra of cellular extracts of HEK293 cells co-transfected with BAP-MHC-Ia and cyt-BirA (control) and, where indicated, with US2 or US11 in the absence (2) or presence of MG132 (MG; 50 μM for 4 h) or Bortezomib(Bort.; 50 μM for 4 h).

    PLoS One 2011 6, e23712. Bortezomib (PS-341) purchased from Selleck.

     

    KKU-M213 was treated with BTZ as indicated. Total cell lysate ( a) and nuclear extract (b) were prepared. Actin and γ -tubulin were loading controls for total and nuclear proteins, respectively.

    2011 Mireia Vila Gasull University of Porto. Bortezomib (PS-341) purchased from Selleck.

  • Mireia Vila Gasull University of Porto. 2011;Mireia Vila Gasull . Bortezomib (PS-341) purchased from Selleck.

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.
Targets
20S proteasome [1]
(Cell-free assay)
0.6 nM(Ki)
In vitro

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. [2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. [1]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 M3riOWN6fG:2b4jpZ{BCe3OjeR?= MWO1NEDPxE1? MWi0PEBp M4XUTmROW09? M2nSfGtqdGy|IHPlcIx{KGK7IH3vdoUhfGijbjC5PUU> MXKxNFQ6QTZ2Mx?=
OVCA 429 MXPGeY5kfGmxbjDBd5NigQ>? M3fwR|MxOCCwTR?= M3HWV|Q5KGh? NGnDO25FVVOR MYfEbZNzfXC2czDpcpRi[3RibYXseIlk\WyudXzhdkB1fW2xcjDzdIhmem:rZIO= MmWyNVA6QTl5Nk[=
RPMI8226 M1nJfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\NXpcyODBibl2= MYG0PEBp NFP4TmVFVVOR MWjJR|UxRTNyIH7N NWPrWJNIOTF|ME[0PFk>
Dox40 NVvmOpRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\sbFE3OTByIH7N NVTIVox6PDhiaB?= NW\DclM4TE2VTx?= NED1SFhKSzVyPUSwJI5O NFqwTFYyOTNyNkS4PS=>
MR20 M2\Bbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUCxNFAhdk1? M4TEXlQ5KGh? NXzqd|RSTE2VTx?= NWnVO4pvUUN3ME2yNEBvVQ>? MmLFNVE{ODZ2OEm=
LR5 NWjWZVVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;kb|ExOCCwTR?= MkL4OFghcA>? MWXEUXNQ Ml;MTWM2OD1{MDDuUS=> NV35fFVIOTF|ME[0PFk>
U266 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfRTIpXOTByIH7N NHPWcZo1QCCq MX\EUXNQ NF3tNo9KSzVyPUOgcm0> NF3nSIMyOTNyNkS4PS=>
IM-9 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXDPZcyODBibl2= M2HOSFQ5KGh? MmHHSG1UVw>? NYrmTplZUUN3ME22JI5O M4e3UlEyOzB4NEi5
Hs Sultan NF;DTYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXqxNFAhdk1? NHXYVZY1QCCq NXzoSZA3TE2VTx?= MV3JR|UxRTJyIH7N NXzpOW15OTF|ME[0PFk>
PAM-LY2 MX\GeY5kfGmxbjDBd5NigQ>? NFf3R28yODBibl2= MYKxNkBp MlHzSG1UVw>? M2fpSGlvcGmkaYTzJG5HNc78QjDhZ5RqfmG2aX;u M4fBN|EyOzVyOUGz
PAM 212 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrmfYhTOTByIH7N NUXtUmM3PzJiaB?= NGnPZmpFVVOR MmPVTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? NX3N[ZdKOTF|NUC5NVM>
PAM-LY2 MnzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjPNVAxKG6P MXW3NkBp M{DiOWROW09? MVTJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? NFn2OXUyOTN3MEmxNy=>
B4B8 M3PNbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWWxNFAhdk1? NXnjeZBGPzJiaB?= MXLEUXNQ NIGxbJJKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= M1zpV|EyOzVyOUGz
B7E3 NUXFc29RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrWNVAxKG6P NI\QOZg4OiCq NILBd5pFVVOR NV3hWJMzUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= MUixNVM2ODlzMx?=
UM-SCC-9 M3PrZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3Wx[lExOCCwTR?= MX[3NkBp NV\0XmFqTE2VTx?= NFrD[lVKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= M4W3NlEyOzVyOUGz
UM-SCC-11B MkjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYGxNFAhdk1? NIPvPHE4OiCq M2HJemROW09? M33lfGlvcGmkaYTzJINmdGxidnnhZoltcXS7 NG\R[JMyOTN3MEmxNy=>
H460 NUKxPWRwTnWwY4Tpc44hSXO|YYm= Mlq2NVAh|ryP M4j3elI1KGh? NGf1W4tFVVOR MXLJcoR2[2W|IFLjcE0zKHCqb4PwbI9zgWyjdHnvckBidmRiY3zlZZZi\2ViY3;ydoVt[XSnZDD3bZRpKEd{LV2gdIhie2ViYYLy[ZN1 NXq2N29XOTJ2OUKxNVc>
U266 NGLGN3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYW1Tmd6PTByIH7nM41t Ml;COFghcA>? MlrzSG1UVw>? MVXJcohq[mm2czDj[YxtKGe{b4f0bC=> NGjv[noyOjZ|MU[xPS=>
ARH77 M{TaVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkD0OVAxKG6pL33s M3zkOFQ5KGh? MkD4SG1UVw>? NHPjT3BKdmirYnn0d{Bk\WyuIHfyc5d1cA>? Mn:3NVI3OzF4MUm=
WAD-1 NVPpW5pLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHGepM2ODBibnevcYw> MX:0PEBp MXnEUXNQ MVPJcohq[mm2czDj[YxtKGe{b4f0bC=> MnH1NVI3OzF4MUm=
U266/LR7 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWq1NFAhdmdxbXy= Moj5OFghcA>? M2\WNWROW09? MkXtTY5pcWKrdIOgZ4VtdCCpcn;3eIg> MWCxNlY{OTZzOR?=
U266/dox4 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3jfIQ2PTByIH7nM41t NGHBfpI1QCCq MmDFSG1UVw>? NGn5THZKdmirYnn0d{Bk\WyuIHfyc5d1cA>? Mni3NVI3OzF4MUm=
RPMI8226/LR5 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUWwbVhCPTByIH7nM41t NHS1OHc1QCCq MVPEUXNQ NWDvZ|hbUW6qaXLpeJMh[2WubDDndo94fGh? MVmxNlY{OTZzOR?=
H460 M2fSW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvjNVAh|ryP M1HqUVczKGh? MojjSG1UVw>? NGryWGpKSzVyPUGwNEBvVQ>? NULR[VlxOTJ4M{G2NlA>
H358 NXm5PXc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLJNVAh|ryP MWm3NkBp MkTiSG1UVw>? NGfGOlhKSzVyPUewJI5O MkfBNVI3OzF4MkC=
H322 NVHY[XpyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfLNVAh|ryP Mn7qO|IhcA>? MmKySG1UVw>? NXXsU2hRUUN3ME22NlAhdk1? Ml7sNVI3OzF4MkC=
H460 NGPHW2NHfW6ldHnvckBCe3OjeR?= MoToNVAxKG6P M2TSOlI1KGh? Ml\FSG1UVw>? NXXqfnlSUW6mdXPld{BIOi2PLYDoZZNmKGG{cnXzeEBidmRidIXieYxqdiCjc4PlcYJtgS2maYPhd5NmdWKueR?= MXuxNlY{OTZ{MB?=
LNCap-Pro5 NVnUVWJsTnWwY4Tpc44hSXO|YYm= NH7JdmUyKM7:TR?= NXnVVXVZPCCq NHrrO2hFVVOR MWnTeIFjcWyrenXzJJA2Ow>? MnPiNVQ3OTJ3M{K=
T29 MYXBdI9xfG:|aYOgRZN{[Xl? MmnyOVAhdk1? M{e1Z|Q5KGhi Mk[1SG1UVw>? M1G5e2lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M3XVTlE3Pzd6MUe5
T29Kt1 NI\P[JhCeG:ydH;zbZMhSXO|YYm= NX\Xc2xGPTBibl2= MVO0PEBpKA>? M37XRWROW09? MlfSTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NGXzWFIyPjd5OEG3PS=>
HCT116 M1\Vb2Fxd3C2b4Ppd{BCe3OjeR?= M2P0d|UxKG6P NV;xZ2RWPDhiaDC= NHOz[mdFVVOR NEjsTG1KdmS3Y3XzJINmdGxiYYDvdJRwe2m| MUixOlc4QDF5OR?=
HKe-3 M4q0XmFxd3C2b4Ppd{BCe3OjeR?= MXe1NEBvVQ>? M{LVPVQ5KGhi MYrEUXNQ NFyzd2JKdmS3Y3XzJINmdGxiYYDvdJRwe2m| MmfSNVY4PzhzN{m=
NB-1691 M2T1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nwblEh|ryP MmC2O|IhcA>? NI[zWopKdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hfG9iNTW= MlLJNVc3QDl4OES=
CHLA-255 NV;sN4Z{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYCxJO69VQ>? NX7ZPJJlPzJiaB?= NGe0cohKdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hfG9iMjW= MnT6NVc3QDl4OES=
SK-N-AS NInweWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\UW|Eh|ryP MX63NkBp NXXIVpl5UW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKHSxIEGwKS=> NGflZ|MyPzZ6OU[4OC=>
NB-1691 MXjGeY5kfGmxbjDBd5NigQ>? M1vNdlExKG6P M1HGOVI1KGh? NFT1NWpUcWewaX\pZ4FvfGy7IILl[JVk\XNiY3XscJMhcW5idHjlJGcxN0dzIIDoZZNm M1juV|E4Pjh7Nki0
CHLA-255 MnjzSpVv[3Srb36gRZN{[Xl? MmjUNVAhdk1? MnO3NlQhcA>? NIryVFVOd2Snc4TsfUBz\WS3Y3XzJINmdGy|IHnuJJRp\SCJMD;HNUBxcGG|ZR?= Mnn5NVc3QDl4OES=
RPMI 8226 Ml;oSpVv[3Srb36gRZN{[Xl? MWiyNEBvVQ>? M3;TfVghcA>? MVfTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> MWGxPVQ{PjB3MB?=
MM.1S NFy0XY1HfW6ldHnvckBCe3OjeR?= MnzWNlAhdk1? M3zVWVghcA>? MV3TbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> NGizeJoyQTR|NkC1NC=>
U266 NFTVU25HfW6ldHnvckBCe3OjeR?= MmT1NlAhdk1? NFLkUGQ5KGh? M3\3eXNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 MVexPVQ{PjB3MB?=
OPM1 M2TNXGZ2dmO2aX;uJGF{e2G7 NYTWT251OjBibl2= NH3UPVY5KGh? NHftTlFUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? M4fERlE6PDN4MEWw
INA6 M4i2TWZ2dmO2aX;uJGF{e2G7 NF;WT3AzOCCwTR?= NYXNeZk4QCCq M333PXNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 NVLyVnFGOTl2M{[wOVA>
OPM2 NHP2[nBHfW6ldHnvckBCe3OjeR?= NIHkNJMzOCCwTR?= M4e1blghcA>? M2W5e3Nq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 NXvYWFJQOTl2M{[wOVA>
RPMI 8226 MlnkSpVv[3Srb36gRZN{[Xl? NIjrWXMzOCCwTR?= NYK0eJpDQCCq M2LuV2lv\HWlZYOgSG5CKHO7boTo[ZNqew>? MnHaNVk1OzZyNUC=
BaF/3 NGewbIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX:xNFAhdk1? NHz3Wog1QCCq MYXJR|UxRTZwMjDuUS=> NGnEN4gzODNyNU[5Ni=>
BaF/3-p210 M{O5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrJdI4zOTByIH7N NIjRSIk1QCCq MoGyTWM2OD12Lkegcm0> M2fWPVIxOzB3Nkmy
TCC-S Mn:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHyU3kyODBibl2= MWW0PEBp M1zFUGlEPTB;Mj64JI5O NIXRWWIzODNyNU[5Ni=>
BaF/3 M{\1c2Z2dmO2aX;uJGF{e2G7 NFHZd283KG6P NGTQeoo1QCCq NITRV4lKdmS3Y3XzJIEh\3KnYYSgS|Eh[2WubD3jfYNt\SCjcoLld5Q> NIHneG0zODNyNU[5Ni=>
BaF/3-p210 NXPE[IVNTnWwY4Tpc44hSXO|YYm= M1XycFYhdk1? NFHrZWM1QCCq Ml\DTY5lfWOnczDhJJNtcWeqdDDHNUBk\WyuLXP5Z4xmKGG{cnXzeC=> M2nmZ|IxOzB3Nkmy
BaF/3-p210 NX7GZYpNTnWwY4Tpc44hSXO|YYm= M4n6WFYhdk1? MnriNlQhcA>? Mn;4VoVlfWOnczD0bIUheGixc4Doc5J6dGG2aX;uJIFv\CC2aHWgZYN1cX[rdImgc4YhWmJ? M4TzOVIxOzB3Nkmy
Raji M3P6bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfSOGNFOSEQvF2= M3zIZVI1KGh? MVPS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? NFvGSIozOTF5MEm4PC=>
LCL-1 NIjuRXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTOfYZIOSEQvF2= M3XQb|I1KGh? MUPS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? NXvpPGl4OjFzN{C5PFg>
LCL-2 MoLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITlT3cyKM7:TR?= MojvNlQhcA>? NVj1dnd1WmWmdXPld{Bk\WyuII\pZYJqdGm2edMg NXXKWFR3OjFzN{C5PFg>
BJAB NHX4fZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETQXXkyKM7:TR?= MWGyOEBp M3n5NXJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= Mn64NlEyPzB7OEi=
SNT-13 M2GyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVOxJO69VQ>? MmrJNlQhcA>? MXLS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? MXKyNVE4ODl6OB?=
SNT-16 M4HpcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFOx[GYyKM7:TR?= NXXSSXdjOjRiaB?= MmnuVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi MYSyNVE4ODl6OB?=
Jurkat MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWSxJO69VQ>? NVLnXolSOjRiaB?= MV3S[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? M{mzcFIyOTdyOUi4
KAI-3 NUDMUnN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4C2VlEh|ryP M1y2N|I1KGh? NWjBcIc3WmWmdXPld{Bk\WyuII\pZYJqdGm2edMg MYiyNVE4ODl6OB?=
SNK-6 M1zyRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\RSGpGOSEQvF2= NHvidGQzPCCq NEfYeFBT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= M1zTd|IyOTdyOUi4
KHYG-1 NIPqfFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\zbVEh|ryP NEO4cXUzPCCq M4LzdnJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= NF;Ze40zOTF5MEm4PC=>
SNT-16 NVjURmJ{SXCxcITvd4l{KEG|c3H5 MYGxJO69VQ>? M13t[FYhcA>? M1rDVmlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MVqyNVE4ODl6OB?=
Jurkat NYK0UJFsSXCxcITvd4l{KEG|c3H5 NIXue2cyKM7:TR?= NGjh[4c3KGh? NX[3fpV6UW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NIjXT4ozOTF5MEm4PC=>
KAI-3 M1PKUWFxd3C2b4Ppd{BCe3OjeR?= NHS1XGMyKM7:TR?= MYO2JIg> NGDoc2dKdmS3Y3XzJINmdGxiYYDvdJRwe2m| NI\ac4szOTF5MEm4PC=>
KHYG-1 NFTYSXhCeG:ydH;zbZMhSXO|YYm= NHm3O5IyKM7:TR?= NFLvUY03KGh? MmjLTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MkHNNlEyPzB7OEi=
SNT-13 MX3BcpRqfmm{YXygRZN{[Xl? MVixJO69VQ>? NUXicY1wOjRiaB?= MlTsTY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJX MX[yNVE4ODl6OB?=
SNT-16 MW\BcpRqfmm{YXygRZN{[Xl? NV7RXmN2OSEQvF2= MlrPNlQhcA>? NGn3ZXlKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ? M4LrdVIyOTdyOUi4
KAI-3 MUPBcpRqfmm{YXygRZN{[Xl? Mn;6NUDPxE1? NUjxbWNsOjRiaB?= MVfJcoR2[2W|IHz5eIlkKGmwZnXjeIlwdiCxZjDFRnY> MXiyNVE4ODl6OB?=
SNK-6 NF7jTHVCdnSrdnnyZYwhSXO|YYm= NIDTPGgyKM7:TR?= MnTLNlQhcA>? MVvJcoR2[2W|IHz5eIlkKGmwZnXjeIlwdiCxZjDFRnY> NUDsbZVIOjFzN{C5PFg>
RAW 264.7 M1rycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7pNVAxKG6P NWfFclhPPDhiaB?= MX\S[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? NYD3N48{OjJ2MkexOVQ>
A375 MVfBdI9xfG:|aYOgRZN{[Xl? M4r0dlExKG6P NVK0SmtwOjRiaB?= MWDJcoR2[2W|IHPlcIwh[XCxcITvd4l{ Mm\NNlMxPzlyOEO=
BLM NHOyXINCeG:ydH;zbZMhSXO|YYm= M4rMelExKG6P MV2yOEBp M1zPfGlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NGDlcY0zOzB5OUC4Ny=>
A375 NH:2U|NCfXSxcHjh[5khSXO|YYm= NV;sb5UzOTBibl2= Mn7ONVIhcA>? MmrmTY5lfWOnczDmc5Ju[XSrb36gc4Yh[XW2b4DoZYdwe2:vZYO= MkHMNlMxPzlyOEO=
BLM MULBeZRweGijZ4mgRZN{[Xl? MX2xNEBvVQ>? M4jhflEzKGh? M{m3[2lv\HWlZYOg[o9zdWG2aX;uJI9nKGG3dH;wbIFod3OxbXXz MUSyN|A4QTB6Mx?=
H1299 NUX4NIZoSXCxcITvd4l{KEG|c3H5 NWTMO|JFQDBibl2= M2LYeFI1KGh? M4q5b2ROW09? Ml\nV4Vve2m2aYrld{BPW0OOQzDj[YxteyC2bzDNV2Mu\GW{aY\l[EBqSzlvaX7keYNm\CCjcH;weI9{cXN? M1rnd|I2OzJ|Nkmz
Hut-78 MkTGSpVv[3Srb36gRZN{[Xl? NV7zR4lnOTByIH7N MoXvNlQhcA>? M1[zTmROW09? M3LXSmRwf26{ZXf1cIF1\XNiVFfGMe6zOSCjbnSgTWwuOTBiZYjwdoV{e2mxbh?= NF7kZ|IzPTZ6MUOzOS=>
H9 MX7GeY5kfGmxbjDBd5NigQ>? MmnoNVAxKG6P MkO4NlQhcA>? NXPMXHN[TE2VTx?= M1HtdGRwf26{ZXf1cIF1\XNiVFfGMe6zOSCjbnSgTWwuOTFiZYjwdoV{e2mxbh?= NXGyNGpZOjV4OEGzN|U>
HH M1XMeGZ2dmO2aX;uJGF{e2G7 NYjrZndJOTByIH7N NHTa[oQzPCCq NWHueHhtTE2VTx?= NVS0eItk\G:5boLl[5Vt[XSnczDUS2Yu|rJzIHHu[EBKVC1zMjDlfJBz\XO|aX;u NXj3eXRqOjV4OEGzN|U>
Hut-78 NYDjToV[VWmpcnH0bY9vKEG|c3H5 NXfBd5A1OTByIH7N M1LIfFI1KGh? MnXkSG1UVw>? MWHS[YR2[2W|IHPlcIwhdWmpcnH0bY9vKGK7IEiw5qCUQTBn NX[3fpVCOjV4OEGzN|U>
HH M4D4eG1q\3KjdHnvckBCe3OjeR?= MUixNFAhdk1? MWWyOEBp MX7EUXNQ M1PmeHJm\HWlZYOgZ4VtdCCvaXfyZZRqd25iYomgPFDjiJN7MTW= MYKyOVY5OTN|NR?=
U937 MVzGeY5kfGmxbjDBd5NigQ>? MlnxNVAxKG6P NYG0cplJPiCq MUXJcoR2[2W|IFnMMVgh\XiycnXzd4lwdiCrbjDMVHMue3SrbYXsZZRm\CCXOUO3JI1i[3KxcHjh[4V{ NWjZenBXOjV5OUG0O|c>
human PBMC NIq4fYdHfW6ldHnvckBCe3OjeR?= NX\JOpRGOTByIH7N M4D5RVI1KGh? M1[2[Wlv\HWlZYOgTWwuQCC{ZXzlZZNm MofCNlU4QTF2N{e=
ES6 NVTHXlR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwMECyNUBvVQ>? MWTTRW5ITVJ?
SK-UT-1 M{XrR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLQN|ROUUN3ME2wMlE3OyCwTR?= MUTTRW5ITVJ?
SH-4 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XsfmlEPTB;MD6xO|Mhdk1? Mme0V2FPT0WU
TE-9 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrUbWpKSzVyPUCuNVgzKG6P MonTV2FPT0WU
A253 M1;Jdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DTOmlEPTB;MD6yNFghdk1? Mm\NV2FPT0WU
no-10 Mor5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjLTWM2OD1yLkKxJI5O M3TmO3NCVkeHUh?=
MMAC-SF M1WxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXkUVNKSzVyPUCuNlE3KG6P MY\TRW5ITVJ?
A101D NVzkXpU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrZc5M1UUN3ME2wMlIzPSCwTR?= MmfaV2FPT0WU
NTERA-S-cl-D1 M2DadWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnnTWM2OD1yLkK0N{BvVQ>? M1jCUXNCVkeHUh?=
8-MG-BA M1HYSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXqyOGdPUUN3ME2wMlI2KG6P NXjyZoVKW0GQR1XS
KNS-42 M3LieGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPaTWM2OD1yLkK1PEBvVQ>? MXzTRW5ITVJ?
LXF-289 M2CwSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkSxTWM2OD1yLkK2PUBvVQ>? M4rlW3NCVkeHUh?=
OVCAR-4 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXITWM2OD1yLkK4PUBvVQ>? NGK4ZlRUSU6JRWK=
LOUCY NHyxWnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonTTWM2OD1yLkK5N{BvVQ>? MWnTRW5ITVJ?
BB65-RCC NVjhNIFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojNTWM2OD1yLkOwOEBvVQ>? NV23cIxsW0GQR1XS
D-542MG MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVji[I1kUUN3ME2wMlMzQSCwTR?= MUHTRW5ITVJ?
ONS-76 Mny3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDrU5htUUN3ME2wMlM{KG6P NW\DV3U1W0GQR1XS
BB30-HNC M1WydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrqW5RoUUN3ME2wMlM{PSCwTR?= MonVV2FPT0WU
KS-1 M2PXSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\PWHY5UUN3ME2wMlM1KG6P M4DSTXNCVkeHUh?=
A388 M4Lue2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjybWpOUUN3ME2wMlM2PiCwTR?= NWL6d5d6W0GQR1XS
ES8 NH;O[HpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13FRmlEPTB;MD60JI5O MonvV2FPT0WU
MZ2-MEL Mkf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTZTWM2OD1yLkSwO{BvVQ>? NYDOdlhDW0GQR1XS
HCC2998 MmOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;RTWM2OD1yLkSxNkBvVQ>? NHv1OYFUSU6JRWK=
D-247MG MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH[zS|BKSzVyPUCuOFE{KG6P M2nTd3NCVkeHUh?=
ACN M1fCVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXe2UHpwUUN3ME2wMlQyPyCwTR?= NYDxV4lKW0GQR1XS
LB2518-MEL NH3Zc3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;5TWM2OD1yLkSyOUBvVQ>? NI\Ne5NUSU6JRWK=
ES1 NXXpRnQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTBwNEOgcm0> NGXafJRUSU6JRWK=
HCE-T Mlq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3ixcGlEPTB;MD60N|khdk1? NE\m[ZJUSU6JRWK=
OS-RC-2 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1G0dWlEPTB;MD60OEBvVQ>? M2K5cXNCVkeHUh?=
MFH-ino NVvEZ4ZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrNdVdnUUN3ME2wMlQ1OyCwTR?= MXHTRW5ITVJ?
OCUB-M NGKwdI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\xdmlEPTB;MD60OFchdk1? NI\SS4tUSU6JRWK=
CP66-MEL MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTBwNEezJI5O NEW3VIFUSU6JRWK=
LB771-HNC MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2K3cmlEPTB;MD60O|Qhdk1? NVjqN4FDW0GQR1XS
DSH1 MlLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M325XGlEPTB;MD60PEBvVQ>? NIW0XFJUSU6JRWK=
HUTU-80 M4DlTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TYdmlEPTB;MD61N|Mhdk1? MU\TRW5ITVJ?
CESS MoHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\VUWlEPTB;MD61N|ghdk1? MVnTRW5ITVJ?
NCI-H747 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPiTWM2OD1yLkWzPUBvVQ>? MVjTRW5ITVJ?
HT-144 MnHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPzTWM2OD1yLkW3OkBvVQ>? NF7zdohUSU6JRWK=
COLO-829 MkD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTZUm1ZUUN3ME2wMlYyPCCwTR?= NHTSdY5USU6JRWK=
A4-Fuk NUf2SGV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4P1d2lEPTB;MD62NlMhdk1? M3vlU3NCVkeHUh?=
GI-ME-N NVTnbYJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTWTWM2OD1yLk[zOEBvVQ>? MojGV2FPT0WU
LB831-BLC M4P5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzzTWM2OD1yLk[0NUBvVQ>? M2rKXnNCVkeHUh?=
HOP-62 NITCe41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\3V5JGUUN3ME2wMlY1PyCwTR?= NGj1WVFUSU6JRWK=
BB49-HNC NXnFWng5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVH6cYFuUUN3ME2wMlY2OiCwTR?= Mn3wV2FPT0WU
D-336MG Mn7IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTBwNkW3JI5O M4DLXnNCVkeHUh?=
TK10 MlznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\ucpJMUUN3ME2wMlY4QSCwTR?= MkCxV2FPT0WU
Ramos-2G6-4C10 NHXuN5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTBwNkmzJI5O MXrTRW5ITVJ?
LB373-MEL-D NVLldYxbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmf0TWM2OD1yLkegcm0> MnfrV2FPT0WU
SF126 NIn1VI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LRRmlEPTB;MD63NFEhdk1? NX;ySXFsW0GQR1XS
UACC-257 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7rTWM2OD1yLkexJI5O NEXa[pRUSU6JRWK=
KINGS-1 NH3FO29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTBwN{KyJI5O MorYV2FPT0WU
LS-513 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1n5SWlEPTB;MD63N|khdk1? NFvJWVhUSU6JRWK=
GI-1 NI\SbXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;3fIpqUUN3ME2wMlc3PCCwTR?= NGGySmVUSU6JRWK=
ES7 M{HmWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7BTWM2OD1yLke2OkBvVQ>? MoDXV2FPT0WU
LB2241-RCC MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjsdmFKSzVyPUCuPFA1KG6P NV7mXWc5W0GQR1XS
D-263MG NITpZYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonkTWM2OD1yLkiwO{BvVQ>? MnjNV2FPT0WU
SW684 M{fze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTBwOEKxJI5O MYLTRW5ITVJ?
ML-2 NIm1W5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DYR2lEPTB;MD64NlEhdk1? M4PPTnNCVkeHUh?=
SK-LMS-1 M3m4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIOweJlKSzVyPUCuPFU1KG6P MVXTRW5ITVJ?
TE-5 NEG5S4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PrfGlEPTB;MD64OlUhdk1? M2LBcXNCVkeHUh?=
QIMR-WIL M{W2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVP1T2ZxUUN3ME2wMlg5QSCwTR?= MWrTRW5ITVJ?
NCI-H1355 NGfhO4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTBwOEm1JI5O MnfBV2FPT0WU
SNB75 NHy5PFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTBwOUGyJI5O M2jBTXNCVkeHUh?=
RXF393 NXPWNZV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTBwOUG0JI5O NUnxZXNqW0GQR1XS
IST-MEL1 NY[2b2NCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlr2TWM2OD1yLkmxO{BvVQ>? NYPJVG5PW0GQR1XS
SF268 MkTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfGXW9MUUN3ME2wMlkzOyCwTR?= MVPTRW5ITVJ?
KALS-1 NXvHfJd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PGVWlEPTB;MD65NlUhdk1? M{jiOnNCVkeHUh?=
HC-1 NWPFWXRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DXOmlEPTB;MD65O|Uhdk1? NVy3[ZpZW0GQR1XS
SW872 MknOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUj6R5k3UUN3ME2wMlk6PiCwTR?= NVHYbI1xW0GQR1XS
PSN1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTFwMEGgcm0> M33O[HNCVkeHUh?=
TE-1 M3HuNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXofo5KSzVyPUGuNFMhdk1? MmHQV2FPT0WU
TE-10 MkLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfMTWM2OD1zLkCzJI5O MULTRW5ITVJ?
RKO MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLOcXlEUUN3ME2xMlA3KG6P NViyR5M2W0GQR1XS
LC-2-ad NIfBOllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fwXWlEPTB;MT6wPEBvVQ>? M2\Jb3NCVkeHUh?=
SK-MM-2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEL6O21KSzVyPUGuNFkhdk1? NEO5ZVdUSU6JRWK=
VA-ES-BJ MlPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnn0TWM2OD1zLkC5JI5O NGjtWW5USU6JRWK=
MZ7-mel NHz3fnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTFwMEmgcm0> MU\TRW5ITVJ?
D-392MG NX;POIF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDYTWM2OD1zLkGgcm0> MUfTRW5ITVJ?
CCRF-CEM MoPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTFwMUOgcm0> M3zOcXNCVkeHUh?=
EM-2 NWXFSopsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzldJhKSzVyPUGuNVYhdk1? MkjyV2FPT0WU
HAL-01 M2Pq[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mly1TWM2OD1zLkG4JI5O NFzLfHZUSU6JRWK=
TE-8 M2Lne2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzqTWM2OD1zLkG5JI5O NYDsZnY2W0GQR1XS
NCI-H1882 M1fPdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrDTWM2OD1zLkKgcm0> NXixNYRiW0GQR1XS
Daudi M{DPR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4f2dGlEPTB;MT6yNkBvVQ>? Mmj5V2FPT0WU
BL-41 Mnr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jRbGlEPTB;MT6yOUBvVQ>? NX;idFBUW0GQR1XS
SR M4HIW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fBSGlEPTB;MT6yOUBvVQ>? M1rMcHNCVkeHUh?=
KM12 NHfCb4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTFwMkegcm0> M37tTnNCVkeHUh?=
K5 NX\HO3VST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XQRWlEPTB;MT6yPEBvVQ>? MXnTRW5ITVJ?
A3-KAW MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjsWIFKSzVyPUGuNlghdk1? NEnLNIhUSU6JRWK=
CMK M2\1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDWTWM2OD1zLkK5JI5O M3\YZnNCVkeHUh?=
Calu-6 M4\iSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPFXFVKSzVyPUGuNlkhdk1? NFTFTJpUSU6JRWK=
IST-SL2 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTFwM{Ggcm0> MVLTRW5ITVJ?
OPM-2 M4LkO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTFwM{Ogcm0> MWHTRW5ITVJ?
DU-4475 NG\XO2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7XTWM2OD1zLkO2JI5O M4LqT3NCVkeHUh?=
ECC12 NX[0SWQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\ldmlEPTB;MT6zO{BvVQ>? MknCV2FPT0WU
L-540 NIDYN5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4K1V2lEPTB;MT6zO{BvVQ>? MlLPV2FPT0WU
CAS-1 Mm\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXpTWM2OD1zLkO3JI5O MWDTRW5ITVJ?
PF-382 M{HVPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHO3[GtKSzVyPUGuOFchdk1? NWPLT3AyW0GQR1XS
LS-411N NX7FUFB[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13JVmlEPTB;MT61N{BvVQ>? M3r1NHNCVkeHUh?=
NCI-H69 NUnxVJl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPldYlFUUN3ME2xMlU1KG6P NGC1[2JUSU6JRWK=
NB12 NWLHdGZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPjTWM2OD1zLkW2JI5O NFroXlVUSU6JRWK=
HEL NFT2V4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnS0TWM2OD1zLk[xJI5O M2jQZXNCVkeHUh?=
GCIY NHjyWWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTFwNkKgcm0> NEf4PWRUSU6JRWK=
EHEB M4nsSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nLSGlEPTB;MT62O{BvVQ>? NV;jZZpGW0GQR1XS
TGBC1TKB MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInqW3dKSzVyPUGuO|Ehdk1? NFHmdYdUSU6JRWK=
KURAMOCHI MnvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUezPFFmUUN3ME2xMlczKG6P NVnQ[HdzW0GQR1XS
U-266 NHv5OIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzTelVKSzVyPUGuO|Yhdk1? NVnBVZZxW0GQR1XS
LC4-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\FSIxRUUN3ME2xMlc6KG6P MW\TRW5ITVJ?
NCI-H2126 NGr2R4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PNbWlEPTB;MT64JI5O MWDTRW5ITVJ?
NCI-H1092 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTFwODDuUS=> NEHGbolUSU6JRWK=
GB-1 NUTTUVNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7aV25KSzVyPUGuPFEhdk1? MUjTRW5ITVJ?
MV-4-11 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYL1R5hzUUN3ME2xMlgzKG6P NVP2RWlmW0GQR1XS
Becker NH7lfFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTFwOEOgcm0> NH3mOXJUSU6JRWK=
MPP-89 Mo\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPqTWM2OD1zLki5JI5O NHPzbYRUSU6JRWK=
BE-13 M{PxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPCTWM2OD1zLkmzJI5O MlHWV2FPT0WU
697 MlT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PZNmlEPTB;MT65PUBvVQ>? NXHTT|V6W0GQR1XS
NKM-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTJibl2= M3\wcnNCVkeHUh?=
NB13 NVrUPZJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTJibl2= M1uwc3NCVkeHUh?=
LS-123 M3XlOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\hT2dKSzVyPUKuNFIhdk1? NH20e3ZUSU6JRWK=
NB17 NXPNe3ZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHnTWM2OD1{LkC0JI5O M1P3PHNCVkeHUh?=
LAN-6 M1\4PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPoV4NGUUN3ME2yMlA2KG6P MXjTRW5ITVJ?
EW-24 NFmwXIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEiyU|NKSzVyPUKuNFghdk1? NYXSUW1ZW0GQR1XS
NOS-1 NV\PTI17T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTJwMUGgcm0> NHnxZ|hUSU6JRWK=
BL-70 M1TSN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfEU4VVUUN3ME2yMlEzKG6P MnLDV2FPT0WU
GT3TKB M4TMS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTJwMUKgcm0> MUjTRW5ITVJ?
HH MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTJwMUOgcm0> NEXGNHhUSU6JRWK=
KE-37 MkWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvkfpRKSzVyPUKuNVMhdk1? MUTTRW5ITVJ?
MOLT-4 M3HnOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPYOnJKSzVyPUKuNVMhdk1? MkDGV2FPT0WU
EKVX Mn;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfGSWdKSzVyPUKuNVQhdk1? NV;LT|VTW0GQR1XS
KGN MnjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTJwMUWgcm0> MoS0V2FPT0WU
ES4 MontS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTJwMU[gcm0> NWjDeXZiW0GQR1XS
SJSA-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDRTWM2OD1{LkKxJI5O NWf5VJpRW0GQR1XS
KMOE-2 NGPubYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVexOGVvUUN3ME2yMlI{KG6P M{LvfHNCVkeHUh?=
NB5 M3[5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTJwMkegcm0> MXnTRW5ITVJ?
BC-1 NWG0OoYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XrUGlEPTB;Mj6zNUBvVQ>? MXPTRW5ITVJ?
NB10 M1HXT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;ZTZhKSzVyPUKuN|Ihdk1? M2fGTnNCVkeHUh?=
RPMI-8226 M3\xfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDobFRMUUN3ME2yMlM2KG6P M2HpXHNCVkeHUh?=
SCC-3 NV;jNJdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPKTWM2OD1{LkO3JI5O MVnTRW5ITVJ?
ARH-77 NUm3fo9nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTJwM{igcm0> NWrqTo0zW0GQR1XS
NCI-H748 NV\iT3dkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVS1fHJSUUN3ME2yMlM6KG6P MnfEV2FPT0WU
KU812 NYK4bVc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3SxTmlEPTB;Mj60NkBvVQ>? NG[1cINUSU6JRWK=
NCI-H64 M3K4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3Bdlh6UUN3ME2yMlQ1KG6P Mo\RV2FPT0WU
NB69 NGj1coRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLjTWM2OD1{LkS2JI5O NF7QfllUSU6JRWK=
KNS-81-FD NHfwcIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\w[HJiUUN3ME2yMlQ5KG6P M33PT3NCVkeHUh?=
LB1047-RCC NXvSelM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHWe4puUUN3ME2yMlU4KG6P MkG3V2FPT0WU
EB-3 NETBRmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLTTWM2OD1{Lk[2JI5O MlnTV2FPT0WU
Mo-T NImxS|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPMTWM2OD1{Lke0JI5O NIfkTppUSU6JRWK=
EW-16 M3TZW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTJwN{Wgcm0> NFHhcXZUSU6JRWK=
CTV-1 M1;DO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3:1dmlEPTB;Mj64JI5O NH:0OpVUSU6JRWK=
ETK-1 NWHYeG1NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17X[GlEPTB;Mj64OEBvVQ>? MXHTRW5ITVJ?
C2BBe1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoG2TWM2OD1{Lki5JI5O MmPTV2FPT0WU
MOLT-16 NX3WZ2hRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoGzTWM2OD1{Lki5JI5O M{\pSnNCVkeHUh?=
SW954 M3;YV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTJwOTDuUS=> NX3wU|hlW0GQR1XS
HT NYrKOGw{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXryXJR4UUN3ME2zMlAzKG6P Mke0V2FPT0WU
KARPAS-299 NIHhTmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjWXoVYUUN3ME2zMlA3KG6P MlO5V2FPT0WU
MONO-MAC-6 M4\MW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTNwMTDuUS=> NFm4UYlUSU6JRWK=
CGTH-W-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrCNXBCUUN3ME2zMlEhdk1? MmnDV2FPT0WU
SK-PN-DW MofaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HqWmlEPTB;Mz6xOEBvVQ>? NEnNSlBUSU6JRWK=
CW-2 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LFN2lEPTB;Mz6yNUBvVQ>? M2L3XXNCVkeHUh?=
SK-N-DZ MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;3TWM2OD1|LkK2JI5O NIL0W4xUSU6JRWK=
NEC8 NX3QW4h5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojXTWM2OD1|LkO1JI5O MoD1V2FPT0WU
LB996-RCC MlWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TmV2lEPTB;Mz60JI5O M3XHOnNCVkeHUh?=
DB M{jDTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYK2W5lGUUN3ME2zMlQyKG6P NFzPOG9USU6JRWK=
TE-15 NHnQNZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTNwNEOgcm0> M1S3XnNCVkeHUh?=
COR-L88 NH3VeoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfITWM2OD1|LkS3JI5O NY\od|RwW0GQR1XS
LAMA-84 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzuW41KSzVyPUOuOFkhdk1? M1q2Z3NCVkeHUh?=
MEG-01 Mlf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTNwNEmgcm0> M2nXb3NCVkeHUh?=
LOXIMVI NWTOfIlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;uTWM2OD1|LkWgcm0> NVnx[XBpW0GQR1XS
RPMI-8402 NIXTXmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHyTWM2OD1|LkWgcm0> NW\tfY9WW0GQR1XS
KARPAS-45 MlX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LnT2lEPTB;Mz61OEBvVQ>? MWrTRW5ITVJ?
HCC1187 MlXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTsO5VoUUN3ME2zMlU1KG6P NFW2WpRUSU6JRWK=
MZ1-PC NXy0VId6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXKTWM2OD1|LkW0JI5O MlHFV2FPT0WU
no-11 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPGTWM2OD1|LkW1JI5O NWWyXmNLW0GQR1XS
EVSA-T NXPKcGh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvyWZVKSzVyPUOuOkBvVQ>? NUPrRnVNW0GQR1XS
DJM-1 MmLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2m5VGlEPTB;Mz62N{BvVQ>? NI\Ib2NUSU6JRWK=
COLO-684 NFXVeVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7hTFRKSzVyPUOuOlYhdk1? NF3BSFJUSU6JRWK=
NMC-G1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHkempqUUN3ME2zMlY5KG6P MmjsV2FPT0WU
LC-1F MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGD1[pNKSzVyPUOuO|Qhdk1? NFvHdnZUSU6JRWK=
RL95-2 MonnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTNwN{mgcm0> MV7TRW5ITVJ?
COLO-320-HSR MmfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjh[2hKSzVyPUOuPVIhdk1? NIm2NJlUSU6JRWK=
RCC10RGB NYrsWI84T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;3NWlEPTB;Mz65N{BvVQ>? MlvFV2FPT0WU
HD-MY-Z NXHpV|BNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTNwOUOgcm0> NFvCUJpUSU6JRWK=
NCI-H2141 NFfKT2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTRwMEWgcm0> Mnq0V2FPT0WU
K-562 NWjiRnVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlu3TWM2OD12LkGyJI5O NGS0WVhUSU6JRWK=
NCI-H1648 M17ZT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLnTWM2OD12LkGzJI5O MWPTRW5ITVJ?
OMC-1 NGDjU5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTsTWM2OD12LkG4JI5O Mkj1V2FPT0WU
LB647-SCLC NED6bldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TqeWlEPTB;ND6yNkBvVQ>? MVLTRW5ITVJ?
TE-12 NI\seHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HXXmlEPTB;ND6yOUBvVQ>? MX;TRW5ITVJ?
NOMO-1 M1ziPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTRwM{Ogcm0> MUHTRW5ITVJ?
Raji NVu5cIc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvoTWM2OD12LkS2JI5O Ml;5V2FPT0WU
NALM-6 M4HWTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nVRmlEPTB;ND60PUBvVQ>? NWTrW5d2W0GQR1XS
HL-60 NWH6TG9sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjlbFlUUUN3ME20MlY4KG6P M3PZd3NCVkeHUh?=
IST-SL1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Dn[GlEPTB;ND62PEBvVQ>? MljnV2FPT0WU
MHH-PREB-1 NYOzZWU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;lTWM2OD12Lki2JI5O Mlj4V2FPT0WU
MHH-NB-11 M4\HfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfGZZhKSzVyPUSuPVEhdk1? M3ftfXNCVkeHUh?=
JiyoyeP-2003 NUP2b2Y4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{[1W2lEPTB;NTDuUS=> MVrTRW5ITVJ?
SBC-1 NV33OIR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIro[Y5KSzVyPUWuNFEhdk1? NH7CNGZUSU6JRWK=
CHP-126 NUPIZZk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTVwME[gcm0> MWTTRW5ITVJ?
LU-139 NGr5WYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTVwMUOgcm0> MXfTRW5ITVJ?
NCI-SNU-5 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTVwMUegcm0> MmXIV2FPT0WU
SW962 M3XPdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTTTWM2OD13LkKxJI5O NEfBRoNUSU6JRWK=
EW-1 M{[zSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTVwM{Ggcm0> NVnSR2ppW0GQR1XS
NCI-H1417 M3naemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mom5TWM2OD13LkWxJI5O MYDTRW5ITVJ?
LU-65 M3LQUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHuTWM2OD13Lki0JI5O MmLmV2FPT0WU
D-502MG M3XRd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\MPI9GUUN3ME22MlM4KG6P MnTwV2FPT0WU
BC-3 Mm\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnG3TWM2OD14Lk[xJI5O MULTRW5ITVJ?
GDM-1 NIDERYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;XZ5dKSzVyPU[uO|chdk1? MYfTRW5ITVJ?
NCI-H2196 MkTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLEPFVKSzVyPU[uPEBvVQ>? NVvtN2lPW0GQR1XS
NB1 M3;QbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;3N5JKSzVyPU[uPFghdk1? M2jDUnNCVkeHUh?=
NCI-H345 NED3fnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPafYZKSzVyPUeuNkBvVQ>? NUfqUYM4W0GQR1XS
SU-DHL-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7YTWM2OD15LkK0JI5O NXjQOWx1W0GQR1XS
JVM-2 NH\XRmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPhTWM2OD15LkK4JI5O NY\heIhSW0GQR1XS
LU-134-A NEL4XHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;heGlEPTB;Nz6zPUBvVQ>? MYHTRW5ITVJ?
NCI-H1694 NV\HbJFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LWO2lEPTB;Nz61PEBvVQ>? M4rrcXNCVkeHUh?=
NCI-SNU-16 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTdwNkWgcm0> M4W1WHNCVkeHUh?=
L-363 NYjnTnU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLOS2lMUUN3ME23Mlchdk1? M17R[HNCVkeHUh?=
KG-1 Mn;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTdwOUSgcm0> MY\TRW5ITVJ?
MN-60 M2\0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlr0TWM2OD16LkG0JI5O NIL5eoNUSU6JRWK=
NB6 NELYUlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;OXWlEPTB;OD60PEBvVQ>? M3fQd3NCVkeHUh?=
MLMA MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\ZNmVKSzVyPUiuPFUhdk1? M3u3N3NCVkeHUh?=
ATN-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfR[IlKSzVyPUiuPFkhdk1? NF;Hd49USU6JRWK=
SK-NEP-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG[0UVJKSzVyPUmuNFEhdk1? MWLTRW5ITVJ?
DMS-114 NELZTFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUS2UpI2UUN3ME25MlYzKG6P M1zMV3NCVkeHUh?=
CTB-1 M1;3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLNTWM2OD17Lk[3JI5O NXrxUFNRW0GQR1XS
NCI-H2081 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTFyLkC5JI5O M2XPe3NCVkeHUh?=
ES5 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTFyLkO4JI5O NHHtWJZUSU6JRWK=
HCC1599 M4TvUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3T4Z2lEPTB;MUGuPVEhdk1? MXTTRW5ITVJ?
NCI-H23 MoTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTF{LkGyJI5O NX\RdW1PW0GQR1XS
NCI-H1581 NVjaZ4RwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjVO2p3UUN3ME2xNk4zQCCwTR?= NHvENJdUSU6JRWK=
JVM-3 MoTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn72TWM2OD1zMj65PUBvVQ>? Mkm5V2FPT0WU
NCI-SNU-1 NUTyUXd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTF|LkG5JI5O NHf5VoNUSU6JRWK=
NB7 NVLvWZpyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Lmd2lEPTB;MUWuPVIhdk1? MnK5V2FPT0WU
JAR NWjWS3lGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7NTWM2OD1zNj6xN{BvVQ>? NV3rO5R{W0GQR1XS
TGW NInH[5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTF4LkS4JI5O MX7TRW5ITVJ?
U-87-MG NG\oNoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjHZmJKSzVyPUG2Mlc3KG6P MXTTRW5ITVJ?
NCI-H1436 NIXtRplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTF5LkCxJI5O M1O3[XNCVkeHUh?=
GOTO MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjrc3NKSzVyPUG3MlA3KG6P MYDTRW5ITVJ?
COLO-800 NFi5flhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4D1OWlEPTB;MUeuOlQhdk1? M3vBWHNCVkeHUh?=
MFM-223 Mnq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYi1bIZZUUN3ME2xO{46OSCwTR?= MVXTRW5ITVJ?
EW-18 MmLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HEPGlEPTB;MUeuPVYhdk1? MYLTRW5ITVJ?
NB14 NEnNVYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFX1VZhKSzVyPUG3Mlk5KG6P MoXOV2FPT0WU
EB2 M4fRdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTF6LkC4JI5O M{fNT3NCVkeHUh?=
EoL-1- NH3lb|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGOxdXZKSzVyPUG4MlMyKG6P NG\uPJJUSU6JRWK=
NCCIT MnGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTF6LkO2JI5O NX33RlV5W0GQR1XS
DG-75 NEHRTFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\EV2Q6UUN3ME2xPE43OSCwTR?= NGrodGZUSU6JRWK=
HCC2218 M1XWemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLPdJRKSzVyPUG5MlUhdk1? M4DqZXNCVkeHUh?=
TE-6 NEnEV|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2OxS2lEPTB;MkCuNFghdk1? NHXnc5dUSU6JRWK=
SF539 NUD5c5A3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MomzTWM2OD1{MD62O{BvVQ>? NGnvZnRUSU6JRWK=
NCI-H446 M4j2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTJzLkG4JI5O M4\aNHNCVkeHUh?=
IST-MES1 M2HW[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLETWM2OD1{Mj63O{BvVQ>? NHe2b5pUSU6JRWK=
NCI-H82 M2HhTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjXSpNKSzVyPUKzMlAzKG6P Mne4V2FPT0WU
HCC2157 NFS3dWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTJ|LkGzJI5O MnPqV2FPT0WU
EW-12 Mon4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LJW2lEPTB;MkOuNVchdk1? M{PlWnNCVkeHUh?=
SIMA MoTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH65NmZKSzVyPUKzMlM5KG6P NUi4ZmFWW0GQR1XS
DOHH-2 NHnMUlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTJ|LkS1JI5O M4rTSXNCVkeHUh?=
IM-9 NYj0W2ltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjMTJJKSzVyPUKzMlU1KG6P NH;hUJJUSU6JRWK=
EC-GI-10 NWniNVV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfhVG5KSzVyPUK0MlI{KG6P M{fJOXNCVkeHUh?=
HDLM-2 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTJ2LkW0JI5O M1rq[HNCVkeHUh?=
LS-1034 NG\ofZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\DdGlEPTB;MkWuO|Uhdk1? NHXHO2VUSU6JRWK=
REH NXy3WZU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLEWGJ5UUN3ME2yOk41OSCwTR?= MnXlV2FPT0WU
LU-165 MkDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoqyTWM2OD1{Nj63NkBvVQ>? MojIV2FPT0WU
NH-12 NHrFOXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETwT2JKSzVyPUK3MlY4KG6P M{\tV3NCVkeHUh?=
WSU-NHL MlXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\oUZZsUUN3ME2yPE4{QSCwTR?= NIPXdlJUSU6JRWK=
ECC4 M3[0V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTJ6Lke5JI5O NUDoZ2VjW0GQR1XS
OCI-AML2 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7YTWM2OD1{OT62PUBvVQ>? NIe1TXBUSU6JRWK=
EW-3 M{m3V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVP3VId5UUN3ME2zNE42QSCwTR?= M1\pT3NCVkeHUh?=
NCI-H526 MoTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3X3S2lEPTB;M{KuOVQhdk1? NYLCcpJJW0GQR1XS
NCI-H719 Mk\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDMdZRXUUN3ME2zOE4{OSCwTR?= NHX4SXBUSU6JRWK=
KARPAS-422 NFHYRXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTN3LkC0JI5O NYnTVVN6W0GQR1XS
SK-MEL-1 M3PzZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTyTWM2OD1|NT6xO{BvVQ>? MmmzV2FPT0WU
ES3 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfB[XZKSzVyPUO1MlE6KG6P NVzWcoppW0GQR1XS
UACC-812 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrJTWM2OD1|NT60OEBvVQ>? M4nV[HNCVkeHUh?=
C8166 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVz2TI54UUN3ME2zOU44KG6P MVrTRW5ITVJ?
MDA-MB-134-VI MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrtOVZKSzVyPUO1Mlg4KG6P NFzycVlUSU6JRWK=
D-283MED Mn70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInNW5FKSzVyPUO3Mlc6KG6P NX;CbGJsW0GQR1XS
SHP-77 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Dwe2lEPTB;M{iuNFMhdk1? M1HQVnNCVkeHUh?=
NCI-H2227 MmizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDTNllKSzVyPUSwMlQ6KG6P M3jwNHNCVkeHUh?=
SKM-1 NWLqbFdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILhS|NKSzVyPUSyMlY{KG6P NUD0dYZuW0GQR1XS
L-428 NX3kbXlGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\ETWM2OD12Mz64OkBvVQ>? NH3yWVdUSU6JRWK=
RPMI-6666 M{Xyfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTR3Lki5JI5O Ml23V2FPT0WU
NCI-H716 MkP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTR6LkixJI5O MmPPV2FPT0WU
DMS-79 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTVyLkexJI5O NUnwR4oyW0GQR1XS
RS4-11 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvEXJVKSzVyPUWwMlg5KG6P MnvVV2FPT0WU
NCI-H720 M1TESGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTVzLkGxJI5O NUHpO5l{W0GQR1XS
MC-CAR M1nvZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2n3dmlEPTB;NUGuOVIhdk1? NEXFV2hUSU6JRWK=
TALL-1 Mmi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnH0TWM2OD13Mz65NUBvVQ>? NF;LZm1USU6JRWK=
NCI-N87 MknMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvvWGdKSzVyPUW0MlE5KG6P MYDTRW5ITVJ?
P30-OHK MlfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M325bmlEPTB;NUSuOlEhdk1? NXL1fJRkW0GQR1XS
LP-1 NXnTTWpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTZzLkK4JI5O MXHTRW5ITVJ?
YT MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTZzLkigcm0> NV;jfo9jW0GQR1XS
MRK-nu-1 Mk\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmC5TWM2OD14MT64NkBvVQ>? NYLnemxPW0GQR1XS
BT-474 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzk[3I4UUN3ME22OUBvVQ>? NX;qZlY5W0GQR1XS
NCI-H322M Mn;yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\hbmZKSzVyPU[2MlEyKG6P MWHTRW5ITVJ?
NCI-H128 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDsTWM2OD15ND63O{BvVQ>? Ml\qV2FPT0WU
KMS-12-PE NXztRWViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfufFYyUUN3ME23Ok4zPCCwTR?= MVvTRW5ITVJ?
KP-N-YS MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoD4TWM2OD15Nj63OEBvVQ>? NYrKcIs6W0GQR1XS
ALL-PO MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nDPGlEPTB;N{euOlYhdk1? M1PSPHNCVkeHUh?=
EW-13 M2Kycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTd5Lke2JI5O NGLpfY5USU6JRWK=
EW-11 NEjuTI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkG2TWM2OD15OD61NkBvVQ>? MnXEV2FPT0WU
SK-N-FI MoHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3sdHhPUUN3ME24NE4zKG6P NX3Wd29iW0GQR1XS
CAL-148 NVu0WVRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;4cnlKSzVyPUixMlg1KG6P M2XGTHNCVkeHUh?=
RL M{Dz[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPmU2JpUUN3ME24Ok4xQSCwTR?= MUnTRW5ITVJ?
AM-38 NEnrUoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3mTWM2OD16OD6wPEBvVQ>? MlzUV2FPT0WU
RH-1 NWGwOGZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETaXoFKSzVyPUm5Mlg2KG6P NWP6UGZpW0GQR1XS
NCI-H1770 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHj3TpZKSzVyPUGwNk41QSCwTR?= MVfTRW5ITVJ?
SIG-M5 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTFyNT6wOkBvVQ>? NID3TFdUSU6JRWK=
GR-ST NHnUV4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUmxdVVpUUN3ME2xNVMvOzRibl2= NV7BXndiW0GQR1XS
ST486 NXTWT2k{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTpTWM2OD1zMUSuNFYhdk1? NXHs[3dVW0GQR1XS
NCI-H1650 NUPQXo9zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfEbolKSzVyPUGxOU4zQSCwTR?= NXzyNYVEW0GQR1XS
MHH-CALL-2 NWPNTVhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\N[o9KSzVyPUGxOU44KG6P MmDrV2FPT0WU
BV-173 NYDwfpBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTF{Mj63NUBvVQ>? M4DIXXNCVkeHUh?=
MC116 NH\YWWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXT3ZY1QUUN3ME2xOFgvQDVibl2= M{Hnd3NCVkeHUh?=
NCI-H524 NHHT[4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnn[W5KSzVyPUG1PU4yKG6P MljhV2FPT0WU
SCLC-21H NUDiT3BpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFH6PG9KSzVyPUG1PU41OSCwTR?= NIKyNJJUSU6JRWK=
NCI-H1304 M4nKe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rOcGlEPTB;MU[5MlIyKG6P NH7ifXBUSU6JRWK=
NCI-H510A M4DXdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fHSGlEPTB;MUi1MlM4KG6P NUi2dY1HW0GQR1XS
NCI-H209 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTF7Nj61NkBvVQ>? MkfQV2FPT0WU
KM-H2 M3m2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTF7Nz6wOUBvVQ>? Mn3DV2FPT0WU
NCI-H1395 NFXINGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\RTWM2OD1{MUCuNVMhdk1? MkTsV2FPT0WU
NCI-H1155 NXToS5VFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPiTWM2OD1{M{CuN|Ihdk1? NEXKWW1USU6JRWK=
COR-L279 Mo\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTJ3Mj6xO{BvVQ>? Mo\GV2FPT0WU
NCI-H1299 MoDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTJ4MT63NUBvVQ>? MUjTRW5ITVJ?
EW-22 NVO3cYlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvhV4drUUN3ME2yOlMvPzVibl2= M3XudnNCVkeHUh?=
SK-MEL-2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfuUmlPUUN3ME2yPFEvQSCwTR?= MlnzV2FPT0WU
KASUMI-1 MnS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHj1SJpKSzVyPUK4N{4xPSCwTR?= MoTJV2FPT0WU
NCI-H187 M3\jTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nKU2lEPTB;Mki3MlA5KG6P MoDLV2FPT0WU
NCI-H2171 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TZOWlEPTB;Mki4MlkzKG6P M325S3NCVkeHUh?=
LNCaP-Clone-FGC Mo\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTJ7NT6yOkBvVQ>? MYrTRW5ITVJ?
NCI-H1522 MlLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjGXZVKSzVyPUOwO{4xPSCwTR?= M1LFSHNCVkeHUh?=
SCH NXO0VlFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojoTWM2OD1|MkKuNlIhdk1? NUHqendiW0GQR1XS
THP-1 MlPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjBTWM2OD1|MkKuOkBvVQ>? M2\kVHNCVkeHUh?=
SNU-C1 M2HKd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLSPXM6UUN3ME2zOlIvODlibl2= NWqzN2RsW0GQR1XS
CA46 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHPfJVKSzVyPUO3N{43OyCwTR?= Mo\FV2FPT0WU
NCI-H1963 M2jrSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTN6Nj6xPUBvVQ>? MoXEV2FPT0WU
DEL M{PaSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfQTWM2OD1|OUGuNlchdk1? M3j5ZXNCVkeHUh?=
TUR M1P4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTN7Nj62NUBvVQ>? Moi5V2FPT0WU
NCI-H226 NHTPdFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrPTWM2OD12MEOuNlMhdk1? NXfn[o9vW0GQR1XS
COLO-668 NYHHOGltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTMdm5bUUN3ME20NFMvPTdibl2= M13uOnNCVkeHUh?=
CPC-N NEn5cVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvnTWM2OD12MEOuO|chdk1? MYfTRW5ITVJ?
NCI-H889 NULJcG9sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEi3cmxKSzVyPUS2NU46OiCwTR?= MnXKV2FPT0WU
J-RT3-T3-5 MnjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnuXJpiUUN3ME21N|IvPTdibl2= MkXVV2FPT0WU
MSTO-211H M1zzS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULENZI3UUN3ME21O|QvOjZibl2= NXfVdoJkW0GQR1XS
SCC-15 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTZ4Nz60O{BvVQ>? NEf0c21USU6JRWK=
SUP-T1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLwSVZKSzVyPU[4Ok4xPCCwTR?= NH;SbGVUSU6JRWK=
DMS-153 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjiTWM2OD15NE[uPFMhdk1? M4m3fnNCVkeHUh?=
MS-1 NF\zdHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHrfm5KSzVyPUe1PU41OiCwTR?= MVfTRW5ITVJ?
TC-YIK M3ztXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13S[WlEPTB;N{ixMlAyKG6P Ml;MV2FPT0WU
RPMI-8866 M1HYVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rxdmlEPTB;MUCwOk4zQCEQvF2= MXTTRW5ITVJ?
KY821 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnRRXJKSzVyPUGwN|YvODRizszN MYDTRW5ITVJ?
P31-FUJ M2W2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPKcnBKSzVyPUGxNVIvPzVizszN NELaXHZUSU6JRWK=
COLO-824 NWC1SlJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFX1TZhKSzVyPUGyOlEvPzhizszN M33sO3NCVkeHUh?=
U-698-M MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHuSXlvUUN3ME2yNlYzNjF3IN88US=> M3HDfHNCVkeHUh?=
TE-441-T MnTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTJ3MkGuO{DPxE1? M1fIdXNCVkeHUh?=
IMR-5 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4S3fGlEPTB;M{SwPU43OiEQvF2= M{i2d3NCVkeHUh?=
NCI-H1838 M1XQfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTRzOE[uN|Ih|ryP MWfTRW5ITVJ?

... Click to View More Cell Line Experimental Data
In vivo The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. [2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. [3]

Protocol

Kinase Assay:

[4]
+ Expand

Kinetic Methods:

In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
Cell Research:

[5]
+ Expand
  • Cell lines: Human multiple myeloma cells line U266
  • Concentrations: ~10 μM
  • Incubation Time: 2 days
  • Method:

    The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer.


    (Only for Reference)
Animal Research:

[3]
+ Expand
  • Animal Models: Human plasmacytoma xenografts RPMI 8226
  • Formulation: Saline
  • Dosages: 1 mg/kg
  • Administration: i.v. twice weekly for 4 weeks, then once weekly
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (197.79 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing. 		5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 384.24
Formula

C19H25BN4O4
CAS No. 179324-69-7
Storage powder
in solvent
Synonyms LDP-341, MLM341

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03607643 Not yet recruiting Cancer of Pancreas|Cancer of Liver|Cancer of Rectum|Cancer of Colon|Cancer Gall Bladder|Myeloma Multiple|Glioblastoma Multiforme Leaf Vertical Inc. January 15 2019 Phase 1|Phase 2
NCT03701321 Not yet recruiting Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma National Cancer Institute (NCI) January 25 2019 Phase 1|Phase 2
NCT03729804 Not yet recruiting Multiple Myeloma University of Chicago December 24 2018 Phase 3
NCT03651128 Not yet recruiting Multiple Myeloma Celgene November 30 2018 Phase 3
NCT03737136 Recruiting Antibody-mediated Rejection Shahid Beheshti University of Medical Sciences November 1 2018 Not Applicable
NCT03652064 Not yet recruiting Multiple Myeloma Janssen Research & Development LLC November 26 2018 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?

  • Answer:

    S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

selleck catalog

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

  • Pan Proteasome Inhibitor

    Ixazomib (MLN2238) : β5 site, IC50=3.4 nM; β1 site, IC50=31 nM; β2 site, IC50=3500 nM.

  • FDA-approved Proteasome Inhibitor

    Carfilzomib (PR-171) : Approved by FDA for multiple myeloma.

  • Newest Proteasome Inhibitor

    Oprozomib (ONX 0912) : Orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM.

  • Classic Proteasome Inhibitor

    ONX-0914 (PR-957) : Selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome.

Related Proteasome Products4

  • VR23 New

    VR23 is a potent proteasome inhibitor with IC50 of 1 nM, 50-100 nM, and 3 μM for trypsin-like proteasomes, chymotrypsin-like proteasomes, and caspase-like proteasomes, respectively.

  • Calpeptin New

    Calpeptin is a potent, cell-permeable calpain inhibitor with ID50 of 52 nM, 34 nM, 138 nM, and 40 nM for Calpain I (porcine erythrocytes), Calpain II (porcine kidney), Papainb, and Calpain I (human platelets), respectively.

  • Marimastat (BB-2516) New

    Marimastat (BB-2516) is a broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 with IC50 of 3 nM, 5 nM, 6 nM, 9 nM and 13 nM, respectively. Phase 3.

  • MG-132

    MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 and 1.2 μM for the inhibition of proteasome and calpain, respectively.

  • Carfilzomib (PR-171)

    Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities.

  • Ixazomib (MLN2238)

    MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM. Phase 3.

    Features:A first-in-class proteasome inhibitor that has improved pharmacokinetics (PK), pharmacodynamics(PD), and antitumor activity in preclinical studies.

  • ONX-0914 (PR-957)

    ONX-0914 (PR-957) is a potent and selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome in a cell-free assay.

    Features:The first highly selective, small molecule inhibitor of the immunoproteasome. Potential use in cancer and autoimmune diseases (e.g. rheumatoid arthritis, inflammatory bowel disease, and lupus).

  • Ixazomib Citrate (MLN9708)

    Ixazomib Citrate (MLN9708) immediately hydrolyzed to MLN2238, the biologically active form, on exposure to aqueous solutions or plasma. MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/Ki of 3.4 nM/0.93 nM in cell-free assays, less potent to β1 and little activity to β2. Phase 3.

    Features:The 1st oral proteasome inhibitor in early stage clinical trials for Multiple Myeloma.

  • Celastrol

    Celastrol is a potent proteasome inhibitor for the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM.

    Features:A potent antioxidant and anti-inflammatory drug.

  • Oprozomib (ONX 0912)

    Oprozomib (ONX 0912) is an orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM. Phase 1/2.

Tags: buy Bortezomib (PS-341) | Bortezomib (PS-341) supplier | purchase Bortezomib (PS-341) | Bortezomib (PS-341) cost | Bortezomib (PS-341) manufacturer | order Bortezomib (PS-341) | Bortezomib (PS-341) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID